Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex 10.8 mg vs 3.6 mg in Advanced Breast Cancer
NCT00322348Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2006
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival at 24 weeks. Started Apr 2006; status: completed.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00322348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322348.